You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Gemcitabine, Docetaxel, and Bevacizumab in Relapsed and Refractory Pediatric Sarcomas

Hingorani, Pooja MD; Eshun, Francis MD; White-Collins, Andrea PNP; Watanabe, Masayo MD

Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e31826b9d25
Clinical and Laboratory Observations

Background: The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients.

Observations: We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months.

Conclusions: These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.

Author Information

Divisions of Hematology and Oncology, Phoenix Children's Hospital, Phoenix, AZ

The authors declare no conflict of interest.

Reprints: Pooja Hingorani, MD, Phoenix Children’s Hospital, 1919 E Thomas Road, Phoenix, AZ 85016 (e-mail:

Received January 12, 2011

Accepted March 27, 2012

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.